Kura Oncology Correlations

KURA Stock

USD 7.26 0.08 1.11%

The current 90-days correlation between Kura Oncology and Replimune Group is 0.23 (i.e., Modest diversification). The correlation of Kura Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Kura Oncology Correlation With Market

Significant diversification

The correlation between Kura Oncology and DJI is 0.02 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Kura Oncology and DJI in the same portfolio, assuming nothing else is changed.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.

Moving together with Kura Stock

0.62	EQ	Equillium	Pair Corr
0.78	ME	23Andme Holding	Pair Corr
0.81	VALN	Valneva SE ADR	Pair Corr
0.89	DNLI	Denali Therapeutics	Pair Corr
0.76	DNTH	Dianthus Therapeutics	Pair Corr
0.79	DOMH	Dominari Holdings	Pair Corr
0.89	DRRX	Durect	Pair Corr
0.93	DTIL	Precision BioSciences	Pair Corr
0.95	VIGL	Vigil Neuroscience	Pair Corr
0.91	VINC	Vincerx Pharma	Pair Corr
0.9	VKTX	Viking Therapeutics	Pair Corr
0.68	VRCA	Verrica Pharmaceuticals	Pair Corr
0.86	VRDN	Viridian Therapeutics Buyout Trend	Pair Corr
0.88	VRPX	Virpax Pharmaceuticals	Pair Corr
0.81	VRTX	Vertex Pharmaceuticals	Pair Corr

Moving against Kura Stock

0.91	DRTS	Alpha Tau Medical	Pair Corr
0.85	DMAC	DiaMedica Therapeutics	Pair Corr
0.82	VCYT	Veracyte Potential Growth	Pair Corr
0.8	VCEL	Vericel Corp Ord	Pair Corr
0.73	CDIOW	Cardio Diagnostics	Pair Corr
0.61	SABSW	SAB Biotherapeutics	Pair Corr
0.33	A	Agilent Technologies	Pair Corr
0.89	DYAI	Dyadic International	Pair Corr
0.85	VRNA	Verona Pharma PLC	Pair Corr
0.72	SRZNW	Surrozen Warrant	Pair Corr
0.7	VSTM	Verastem	Pair Corr
0.58	DVAX	Dynavax Technologies	Pair Corr
0.54	KTTAW	Pasithea Therapeutics	Pair Corr
0.35	VYNE	Vyne Therapeutics	Pair Corr

Related Correlations Analysis

	PTGX	MRUS	REPL	CERE	KALV	CRNX	THRX	VRDN	GRCL	GLUE
PTGX		0.89	0.26	0.25	0.93	0.7	0.65	0.87	-0.78	0.19	PTGX
MRUS	0.89		0.04	0.25	0.94	0.67	0.63	0.94	-0.83	0.12	MRUS
REPL	0.26	0.04		0.27	0.09	0.49	0.35	0.1	0.16	0.59	REPL
CERE	0.25	0.25	0.27		0.18	0.41	0.36	0.25	-0.11	0.12	CERE
KALV	0.93	0.94	0.09	0.18		0.68	0.62	0.92	-0.81	0.04	KALV
CRNX	0.7	0.67	0.49	0.41	0.68		0.83	0.69	-0.46	0.44	CRNX
THRX	0.65	0.63	0.35	0.36	0.62	0.83		0.64	-0.46	0.35	THRX
VRDN	0.87	0.94	0.1	0.25	0.92	0.69	0.64		-0.8	0.09	VRDN
GRCL	-0.78	-0.83	0.16	-0.11	-0.81	-0.46	-0.46	-0.8		0.09	GRCL
GLUE	0.19	0.12	0.59	0.12	0.04	0.44	0.35	0.09	0.09		GLUE
	PTGX	MRUS	REPL	CERE	KALV	CRNX	THRX	VRDN	GRCL	GLUE

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

KALV	+ 0.94	MRUS
VRDN	+ 0.94	MRUS
KALV	+ 0.93	PTGX
VRDN	+ 0.92	KALV
MRUS	+ 0.89	PTGX
VRDN	+ 0.87	PTGX

High negative correlations

GRCL	- 0.83	MRUS
GRCL	- 0.81	KALV
GRCL	- 0.8	VRDN
GRCL	- 0.78	PTGX
GRCL	- 0.46	THRX
GRCL	- 0.46	CRNX

Risk-Adjusted Indicators

There is a big difference between Kura Stock performing well and Kura Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kura Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
PTGX	2.12	(0.33)	0.00	(0.53)	0.00	0.00	3.70	(4.10)	16.19
MRUS	2.08	(0.39)	0.00	1.28	0.00	0.00	3.33	(4.96)	15.98
REPL	3.04	0.02	0.01	0.04	3.44	(3.64)	5.66	(5.26)	46.30
CERE	0.77	0.08	0.05	(0.73)	0.94	(1.02)	1.91	(1.59)	6.40
KALV	3.04	(0.48)	0.00	(0.60)	0.00	0.00	6.22	(5.26)	15.83
CRNX	2.37	(0.50)	0.00	(0.44)	0.00	0.00	3.10	(7.53)	24.78
THRX	5.44	(0.51)	0.00	0.28	0.00	0.00	11.75	(8.57)	90.33
VRDN	2.89	(0.32)	0.00	(0.66)	0.00	0.00	4.19	(6.93)	29.75
GRCL	5.71	1.44	0.19	(1.40)	6.35	(6.70)	16.34	(6.25)	52.11
GLUE	5.64	0.75	0.15	2.00	4.70	(8.18)	10.21	(8.46)	103.72

Kura Oncology Corporate Management

Kathleen Ford	Chief Officer	Profile
Mollie MD	Executive Development	Profile
Francis Burrows	Senior Research	Profile
Roger Bakale	Clinical CMC	Profile
JD Esq	Chief Secretary	Profile
Marc MD	Advisor	Profile
Stephen MD	Chief Officer	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC